Clinical Challenges: Treating AML With IDH1 and IDH2 Mutations

(MedPage Today) -- About 20% of acute myeloid leukemia (AML) harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2.
Within the last decade, treatment for these patients "has changed significantly" with the development of...